Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma
HAEMATOLOGICA(2017)
摘要
Diffuse large B-cell lymphoma (DLBCL) is a group of clinically aggressive and heterogeneous malignancies, of which approximately 60% can be cured with anthracycline-based chemoimmunotherapy. Based on gene expression profiling, DLBCL can be classified into two molecularly distinct subgroups showing
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络